Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effect of Sevelamer on P-cresyl Sulfate in CKD

Trial Profile

Effect of Sevelamer on P-cresyl Sulfate in CKD

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 28 Feb 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sevelamer (Primary)
  • Indications Hyperphosphataemia; Renal failure
  • Focus Therapeutic Use
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 23 Feb 2015 Planned primary completion date changed from 1 Nov 2014 to 1 May 2015 as reported by ClinicalTrials.gov record.
    • 29 Oct 2014 Design changed from open to randomizes, single blind, parallel; single arm to 2 arms; inclusion/ exclusion criterion changed; second arm is continuously changing between no arm to calcium carbonate, now it is placebo.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top